New study: can a biologic drug help diverse patients breathe better and smell again?

NCT ID NCT05246267

Recruiting now Disease control Sponsor: Montefiore Medical Center Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study is testing whether adding dupilumab to standard steroid nasal sprays improves symptoms and sense of smell in people with chronic sinusitis and nasal polyps. It focuses on a diverse, mostly minority group of 60 adults. Participants will receive dupilumab injections and be monitored for changes in symptom scores and smell tests.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Dupilumab (a biologic drug given as an injection)
What this could lead to: If successful, this could show that dupilumab works well for nasal polyps in a diverse, mostly minority population, helping to reduce symptoms and improve quality of life.
What could go wrong: This is a small, early-stage study with only 60 participants, so results may not apply to everyone. Dupilumab can cause side effects like injection site reactions and allergic reactions.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CHRONIC RHINOSINUSITIS WITH NASAL POLYPS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CHRONIC RHINOSINUSITIS WITH NASAL POLYPS

Contacts and locations

Locations

Montefiore Medical Center
RECRUITING

The Bronx, New York, 10461, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.